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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S217containing 50 % shells and 50% seeds (by weight) and the other version
containing 70% of shells and 30% of seeds (by weight). All animals 16
dogs and 16 horses were treated for a time period of three month, the
dose was 0.3 g pr kg daily, and data was lumped together. The human
studies also tested two different versions of the same shell and seed
containing Rose-hip remedy: The daily dose of one version was 1.2 g
seeds and a similar amount of shells (A version) and the daily dose of
the version (B) was 0.2 g seeds combined with 1.8 g shells.
The human study was performed in two groups of middle aged patients
with modest osteoarthritis. A seasonal variation is reported for CRP
(higher during winter), and both groups started treatment late autumn.
A number of 43 patients were given high dose seed version and 40 other
patients were given corresponding placebo. Another group of 32
patients (B group) were given the low seed version and corresponded to
30 patients on placebo. Data given are mean +/- SD. Wilcoxon test for
matched pairs was used within groups and Mann-Whitney when
comparing placebo and active treatment. A p level less than 0.050 was
regarded as statistically signiﬁcant.
Results: Treatment with the high seed level resulted in a statistically
signiﬁcant reduction in chemotaxis from 28.6 +/- 13.5 to 5.6 +/- 3.4 in
a group of eight animals (p<0.010). A modest and insigniﬁcant increase
was observed in a placebo group of identical magnitude, p <0.050
comparing the two groups. The low dose seed preparation, when tested
in another eight animals resulted in an insigniﬁcant 3% increase of
chemotaxis (p<0.830). No change in chemotaxis was observed in the
placebo group and therewere no signiﬁcant difference between groups.
Patients reaction to the high seed and low seed preparation supported
the observations from animal studies. Treated with the A version (1.2 g
seeds daily) resulted in a insigniﬁcant CRP reduction from 2.07 +/- 2.19
to 1.68 +/- 1.28 mg/l, a reduction of 18%. In the placebo group CRP levels
increased statistically signiﬁcant from 1,43 +/- 0.91 to 1.89 +/- 1.35 mg/l
(p<0.014) an increase which is most likely due to reported seasonal
variation. The two groups were signiﬁcantly different from each other
as indicated by a Mann-Whitney p value of 0.042. In the B group
receiving low dose seed treatment (0.2 g daily) there was a modest and
insigniﬁcant increase of 20% in CRP levels, which was not signiﬁcantly
different when compared to observations from the corresponding
placebo group (p<0.339).
Conclusion: The present data suggest that Rose-hip seeds are of
importance to keep the optimal anti-inﬂammatory proﬁle in Rose-hip
preparations.409
AN ORAL PREPARATION CONTAINING HYLAURONIC ACID
(ORALVISC) CAN NORMALIZE THE TURNOVER OF HYALURONIC
ACID IN SYNOVIAL FLUID OF OSTEOARTHRITIC KNEE PATIENTS
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Purpose: Osteoarthritis (OA) is a degenerative joint disease in which
articular cartilage matrix is no longer in homeostatic balance, resulting
in a net loss of chondroitin sulfate (CS)-rich glycosaminoglycans (GAGs).
The pro-inﬂammatory environment of synovial ﬂuid has been shown to
result in an increase in hyaluronic acid (HA) turnover. Consequently the
turnover of CS and HA are considered key parameters to evaluate the
degree and evolution of OA. We conducted a double blind randomized
clinical trial to determine if there would be changes in turnover of CS
and HA in the synovial ﬂuid (SF) of knee OA patients treated with
a patented hyaluronic acid formulation for oral use (Oralvisc) as
compared to placebo.
Methods: 51 symptomatic knee OA patients were recruited sequentially
at the time of an outpatient visit for OA. Subjects were between the ages
of 50-75 years, had knee effusion, and a pain visual analog score (VAS)
>50mm. 40 patients completed the study, 21 had been randomly
selected to receive 80 mg daily of Oralvisc, and the remaining 19 had
identical appearing placebos. Each month they were evaluated for VAS
and WOMAC pain and joint function. A subset of 10 subjects per
treatment group began a 2-day long oral administration of heavy water
(35 mL 2H2O TID for 2 days) at the conclusion of the treatment phase
(Week 12), followed by a synovial ﬂuid aspiration in the affected knee.
Synovial ﬂuid lavage samples were analyzed for 2H-labeling of
component GAGs by gas chromatography/ mass spectrometry (GC/MS)
to obtain fractional synthesis rates of HA and CS in SF.Results: The age, sex, race, BMI, KL scores, as well as VAS pain and
WOMAC function were balanced between groups at the beginning of
the trial. Treatment with oral HA during 3 months resulted in a signif-
icant improvement in VAS pain (p¼0.0035), WOMAC pain (p¼0.0259)
and WOMAC function (p¼0.0132) compared to placebo. The stable-
isotope-mass spectrometry method was successfully implemented for
the clinical study of SF GAG kinetics. The rate of HA turnover was
0.780.42 / day (i.e., 78% per day) in placebo-treated OA patients (n¼10;
Fig. 1). With 12 weeks of oral HA treatment, the mean rate of HA
turnover declined by 45% to 0.420.24 / day (p¼ 0.046). While we have
not directly compared the rate of HA turnover in normal vs. osteoar-
thritic knees, comparison of the current results with data from
a previous study in ACL patients suggests that these osteoarthritis
patients (0.78 / d) have elevated HA turnover relative to “normal”
subjects (0.25 / d), and that oral HA partially normalized the HA turn-
over rate. CS molecules in the SF were also highly enriched, with the
majority of the patients recording the maximum measureable turnover
rate for this assay (>140% / day). Thus, virtually all of the SF-derived CS
was recently synthesized, suggesting a defect in the retention of
potential repair molecules in osteoarthritic cartilage.
Conclusions: This is the ﬁrst study of its kind to show that the use of an
oral HA (Oralvisc) agent in knee OA patients can lead to a signiﬁcant
impact on HA turnover in synovial ﬂuid. The normalization in HA
turnover was paralleled by an overall decrease in pain scores and
improvement in joint function. Further studies are needed to investi-
gate its mechanism but this novel form of oral HA may provide a safe
alternative treatment to correct the homeostatic imbalances in the
progression of OA.
Figure 1. Turnover rate of HA in the knee synovial ﬂuid of osteoarthritic patients. Bar
shows the group mean (ANOVA p ¼ 0.046).
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SULFORAPHANE REPRESSES MATRIX-DEGRADING PROTEASES AND
PROTECTS CARTILAGE FROM DESTRUCTION IN VITRO AND IN VIVO
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Purpose: Broccoli is rich in glucoraphanin (a glucosinolate). When
broccoli is cut or chewed, glucoraphanin is converted by an enzyme,
myrosinase, to sulforaphane (an isothiocyanate). Similar compounds
are derived from other cruciferous vegetables and these compounds are
therefore accessible via the diet. Sulforaphane (SFN) has been reported
to regulate signalling pathways relevant to chronic diseases. Our study
investigated whether sulforaphane can abrogate cartilage destruction
in osteoarthritis and examined mechanism of action in chondrocytes.
Methods: The bovine nasal cartilage explant model (BNC) and desta-
bilisation of medial meniscus (DMM) murine model of osteoarthritis
were used to study chondroprotection by SFN. Histone acetylation, gene
expression, transcription factors nuclear factor (erythroid-derived 2)-
like 2 (Nrf2) and nuclear factor kappaB (NF-kB) signalling were
examined.
